173 related articles for article (PubMed ID: 11550800)
1. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations.
Semczuk A; Skomra D; Cybulski M; Jakowicki JA
Histochem J; 2001 Apr; 33(4):193-200. PubMed ID: 11550800
[TBL] [Abstract][Full Text] [Related]
2. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome.
Semczuk A; Berbeć H; Kostuch M; Cybulski M; Wojcierowski J; Baranowski W
J Cancer Res Clin Oncol; 1998; 124(12):695-700. PubMed ID: 9879831
[TBL] [Abstract][Full Text] [Related]
3. K-ras exon 2 point mutations in human endometrial cancer.
Semczuk A; Schneider-Stock R; Berbec H; Marzec B; Jakowicki JA; Roessner A
Cancer Lett; 2001 Mar; 164(2):207-12. PubMed ID: 11179836
[TBL] [Abstract][Full Text] [Related]
4. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.
Alexander-Sefre F; Salvesen HB; Ryan A; Singh N; Akslen LA; MacDonald N; Wilbanks G; Jacobs IJ
Gynecol Oncol; 2003 Oct; 91(1):218-25. PubMed ID: 14529685
[TBL] [Abstract][Full Text] [Related]
5. Studies on ras oncogene activation in endometrial carcinoma.
Fujimoto I; Shimizu Y; Hirai Y; Chen JT; Teshima H; Hasumi K; Masubuchi K; Takahashi M
Gynecol Oncol; 1993 Feb; 48(2):196-202. PubMed ID: 8428691
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma.
Cherchi PL; Marras V; Capobianco G; Ambrosini G; Piga MD; Fadda GM; Rosas N; Dessole S
Eur J Gynaecol Oncol; 2001; 22(6):451-3. PubMed ID: 11874080
[TBL] [Abstract][Full Text] [Related]
7. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
8. Proliferation index determined by MIB-1 and recurrence in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 Jun; 61(3):373-7. PubMed ID: 8641618
[TBL] [Abstract][Full Text] [Related]
9. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
10. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
[TBL] [Abstract][Full Text] [Related]
11. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases.
Russo A; Migliavacca M; Bazan V; Maturi N; Morello V; Dardanoni G; Modica G; Bazan P; Albanese I; La Farina M; Tomasino RM
Cell Prolif; 1998; 31(3-4):139-53. PubMed ID: 9853427
[TBL] [Abstract][Full Text] [Related]
14. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
15. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of proliferative index and cell cycle protein expression in choroid plexus tumors in children.
Carlotti CG; Salhia B; Weitzman S; Greenberg M; Dirks PB; Mason W; Becker LE; Rutka JT
Acta Neuropathol; 2002 Jan; 103(1):1-10. PubMed ID: 11837741
[TBL] [Abstract][Full Text] [Related]
17. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract.
Chowdhury GM; Kojima K; Kanayama H; Tsuji M; Kurokawa Y; Kagawa S
Cancer; 1996 Aug; 78(4):827-33. PubMed ID: 8756378
[TBL] [Abstract][Full Text] [Related]
18. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of tumour cell proliferation in squamous cell carcinomas of the oesophagus.
Sarbia M; Bittinger F; Porschen R; Dutkowski P; Torzewski M; Willers R; Gabbert HE
Br J Cancer; 1996 Oct; 74(7):1012-6. PubMed ID: 8855967
[TBL] [Abstract][Full Text] [Related]
20. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
Veronese SM; Maisano C; Scibilia J
Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
